Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Transformational technology

Big data, the cloud and the value of insights

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

Deal Watch August 2016

Pfizer's hat trick as well as Sanofi, GlaxoSmithKline, Boehringer Ingelheim and more are featured in this month's round-up

- PMLiVE

Pfizer launches app to help patients manage depression

Hopes the Moodivator app will complement treatment and support care teams

- PMLiVE

A new era of collaboration

Looking at the factors driving this change and assessing the benefits

- PMLiVE

Pfizer appoints chief scientific officer

Dr Ole Isacson will lead the neuroscience research unit

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links